Pacira Biosciences, Stock Investor Sentiment

PCRX Stock  USD 16.91  0.27  1.62%   
Slightly above 52% of Pacira BioSciences,'s investors are presently thinking to get in. The analysis of overall sentiment of trading Pacira BioSciences, stock suggests that some investors are interested at this time. Pacira BioSciences,'s investing sentiment can be driven by a variety of factors including economic data, Pacira BioSciences,'s earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

52

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Pacira BioSciences,'s input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Pacira BioSciences,.

Pacira Historical Sentiment

Although Pacira BioSciences,'s investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Pacira, such as negative comments on social media and news outlets, may cause fear in the market and push Pacira BioSciences,'s investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Pacira.
  

Pacira BioSciences, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pacira BioSciences, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pacira BioSciences, Historical Investor Sentiment

Investor biases related to Pacira BioSciences,'s public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira BioSciences,. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pacira BioSciences,'s market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacira BioSciences, and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Pacira BioSciences, news discussions. The higher the estimate score, the more favorable the investor's outlook on Pacira BioSciences,.
over six months ago at benzinga.com         
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for ...
benzinga news
over six months ago at investing.com         
Paciras gene therapy gets FDAs first osteoarthritis RMAT nod
Investing News at Macroaxis
over six months ago at thelincolnianonline.com         
Pacira BioSciences, Inc. Director Sells 2,754,000.00 in Stock
news
over six months ago at simplywall.st         
Independent Director Of Pacira BioSciences Sold 85 percent Of Their Shares
Simply Wall St News at Macroaxis
over six months ago at gurufocus.com         
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc
Yahoo News
over six months ago at www.macroaxis.com         
Disposition of 90000 shares by Gary Pace of Pacira Pharmaceuticals at 30.6 subject to Rule 16b-3
Macroaxis News
over six months ago at investing.com         
JPMorgan sets 45 target on Pacira stock with Overweight rating
Investing News at Macroaxis
over six months ago at investing.com         
Disposition of 28257 shares by Gary Pace of Pacira Pharmaceuticals at 30.81 subject to Rule 16b-3
Investing News at Macroaxis
over six months ago at streetinsider.com         
JPMorgan Assumes Pacira Pharmaceuticals at Overweight
Street Insider News
over six months ago at finance.yahoo.com         
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Con...
Yahoo News
over six months ago at finance.yahoo.com         
Disposition of 1066 shares by Gary Pace of Pacira Pharmaceuticals at 29.67 subject to Rule 16b-3
Yahoo News
over six months ago at thelincolnianonline.com         
Sherbrooke Park Advisers LLC Acquires New Position in Pacira BioSciences, Inc.
news
over six months ago at thelincolnianonline.com         
Pacira BioSciences Rating Reiterated by Needham Company LLC
news
over six months ago at simplywall.st         
Pacira BioSciences Full Year 2023 Earnings EPS Beats Expectations
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pacira BioSciences, that are available to investors today. That information is available publicly through Pacira media outlets and privately through word of mouth or via Pacira internal channels. However, regardless of the origin, that massive amount of Pacira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pacira BioSciences, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pacira BioSciences, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pacira BioSciences,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pacira BioSciences, alpha.

Pacira BioSciences, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 5773 shares by Lauren Riker of Pacira Pharmaceuticals at 38.52 subject to Rule 16b-3
09/10/2024
2
Disposition of 500 shares by Daryl Gaugler of Pacira BioSciences, at 12.86 subject to Rule 16b-3
09/13/2024
3
Pacira wins Exparel Medicare J-code
10/03/2024
4
Disposition of 1066 shares by Pace Gary W of Pacira BioSciences, at 29.67 subject to Rule 16b-3
10/11/2024
5
Acquisition by Brege Laura of 1000 shares of Pacira BioSciences, at 12.81 subject to Rule 16b-3
10/25/2024
6
Analysts Estimate Moderna to Report a Decline in Earnings What to Look Out for
10/31/2024
7
Acquisition by Shawn Cross of 75000 shares of Pacira BioSciences, subject to Rule 16b-3
11/01/2024
8
Acquisition by Shawn Cross of 200000 shares of Pacira BioSciences, at 16.45 subject to Rule 16b-3
11/04/2024
9
Pacira BioSciences Inc Q3 2024 Everything You Need To Know Ahead Of Earnings
11/05/2024
10
Pacira Q3 Earnings Snapshot
11/06/2024
11
Pacira BioSciences Inc Q3 2024 Earnings Call Highlights Strong Financial Position ...
11/07/2024
12
Pacira BioSciences Buy Rating Reiterated at Needham Company LLC
11/11/2024
13
Pacira BioSciences SWOT analysis stock faces patent challenges amid growth initiatives
11/13/2024
14
Pacira BioSciences, Inc. Shares Sold by Global Alpha Capital Management Ltd. - MarketBeat
11/20/2024
15
Pacira BioSciences Inc Shares Gap Down to 16.49 on Nov 26
11/26/2024

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.